Stephen Feider Sells 6,676 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 6,676 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $84,184.36. Following the sale, the chief financial officer directly owned 166,053 shares of the company’s stock, valued at $2,093,928.33. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Trading Up 11.6%

Shares of NASDAQ BBNX opened at $13.89 on Friday. The stock has a market cap of $618.94 million, a PE ratio of -9.20 and a beta of 3.40. The company has a 50-day moving average of $10.88 and a 200 day moving average of $17.21. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The firm had revenue of $27.63 million for the quarter. On average, sell-side analysts forecast that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics recently said it is publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support transparency and commercial momentum. Article Title
• Neutral Sentiment: Several insider stock sales were disclosed, but the company said they were made to cover tax obligations related to equity award vesting, making the impact less concerning than discretionary selling.
• Negative Sentiment: Johnson Fistel and Robbins LLP announced investigations into Beta Bionics and its officers over possible securities-law violations tied to investor losses and slower new patient start growth, creating a legal overhang. Article Title

Hedge Funds Weigh In On Beta Bionics

Hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in Beta Bionics during the 1st quarter valued at about $29,000. EverSource Wealth Advisors LLC increased its holdings in Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares in the last quarter. Summit Securities Group LLC purchased a new position in Beta Bionics during the 4th quarter valued at about $52,000. Legal & General Group Plc increased its holdings in Beta Bionics by 197.4% during the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after acquiring an additional 2,639 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares in the last quarter.

Analyst Ratings Changes

BBNX has been the subject of a number of recent research reports. Bank of America decreased their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. The Goldman Sachs Group reduced their target price on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Truist Financial reduced their target price on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Robert W. Baird reduced their target price on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. Finally, Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.